Navigation Links
Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
Date:5/21/2012

MUNICH, May 21, 2012 /PRNewswire/ --

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

Principal investigator Prof. Martin Cowie, of the Royal Brompton Hospital in London said, "SERVE-HF is the world's largest study for any aspect of sleep-disordered breathing [SDB], and it has involved significant collaboration among sleep physicians, respiratory physicians and cardiologists across Europe."

Co-principal investigator, Prof. Helmut Teschler, Medical Director at the Department of Pneumology, Ruhrland Clinic, Essen, added, "This study is so important because SDB in heart failure patients is a very common occurrence, particularly in men.  Given that at least 50% of men with heart failure also suffer from moderate to severe SDB, treatment of SDB could be vital to improving heart failure outcomes in the future."

Patients with heart failure may have an abnormal waxing and waning breathing pattern called Cheyne-Stokes respiration (CSR) with CSA.  Previous studies have demonstrated that such patients have a poor quality of life as well as increased mortality, but that they may do better and live longer if they are treated with assisted ventilation during sleep.

The SERVE-HF study hopes to provide more conclusive evidence of the health benefits of treating SDB in heart failure patients, and on a much larger scale.  The study is being conducted at more than 80 sites in Germany, France, the UK, Norway, Sweden, Denmark, Finland, Australia and the Czech Republic.

The primary goal of the study is to determine whether managing CSR-CSA with ResMed's proprietary adaptive servo-ventilation technology (found in its AutoSet CS™ and VPAP™ Adapt devices) increases survival rates and decreases the burden of hospitalizations in this patient population.  Adaptive servo-ventilation is an intelligent method of non-invasive ventilation that continuously monitors and stabilizes the breathing patterns of individuals with SDB throughout the night.

"We've designed the study not only to assess survival rates but also to see if adaptive servo-ventilation improves quality of life, sleep, and physiologic changes associated with heart failure, such as enlarged hearts," stated Prof. Cowie.

Despite the long-established links between SDB and heart disease, SDB diagnosis and management remain in the realm of sleep or respiratory medicine, rather than cardiology. However, favorable SERVE-HF results would be likely to trigger major changes within this field, including greater cardiologist involvement in SDB management.

"Tight collaboration between cardiologists and sleep physicians is needed if SDB care is to improve worldwide. The findings of the SERVE-HF study may ensure that this happens in the future," Prof. Teschler commented.

Additional study information, updates, and news can be obtained at the dedicated SERVE-HF study website http://www.servehf.com.

About ResMed

ResMed is a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit http://www.resmed.com.

For further information, including a backgrounder on the study and bios of the principal investigators, please contact:


Kristine Morrill at Kommunica@medeuronet
Email : kmorrill@medeuronet.com
Phone : +44-7787-137-962


'/>"/>
SOURCE ResMed
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
2. Trapollo LLC Teams with Humana Cares for Landmark Telehealth Deployment to 1600 Humana Subscribers
3. Landmark Study Finds Expensive Catheter Procedure to Close Hole in Heart No More Effective Than Medical Therapy to Prevent Strokes
4. The Appellate Division of State Supreme Court has Upheld a Landmark 2010 Products Liability Verdict Which Found Cybex International Responsible for Catastrophic Injuries Suffered by a Cheektowaga Woman
5. HSCA, Group Purchasing Industry Endorse Landmark Environmental Tool From Practice Greenhealth to Help Guide Selection and Procurement of Environmentally Preferable Products for Hospitals
6. Kimberly-Clark Health Care Receives Landmark FDA Clearance for Pediatric Face Mask
7. Landmark Stryker Trial Establishes Coiling as Safe and Effective Treatment for Ruptured and Unruptured Aneurysms
8. SurgiCount Medical Announces Expanded Honor Roll Hospital Users, Landmark Product Usage Milestones Achieved
9. AVAC Says Results of New PrEP Trials Provide Clear Evidence that Antiretroviral Drugs for Prevention Can Help End the AIDS Epidemic; Calls for Quick Action to Move Landmark HIV Prevention Results Toward Lifesaving Programs
10. Consortium Opens Landmark Personalized Medicine Childrens Cancer Trial
11. Landmark Patents Issued for ViewRay Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Site Profile: --> Site ... People, announced their latest primary healthcare case study where speech recognition ... and to save the practice money. Site Profile: ... Challenge: --> ,- Wirral CCG ,- VoicePower client since ... Wirral CCG ,- VoicePower client since 2013 Challenge: ...
(Date:2/5/2016)... Feb. 5, 2016 ... the "Global Obstetrics Partnering 2010-2016: Deal ... to their offering. --> http://www.researchandmarkets.com/research/hcdvg6/global_obstetrics ... "Global Obstetrics Partnering 2010-2016: Deal trends, ... their offering. --> Research and ...
(Date:2/4/2016)...  Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, announced today that it has ... Morgan Stanley & Co. LLC to repurchase $325 million ... the Company,s previously authorized program to repurchase up to ... --> --> Under the ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air ... variety of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, ... , For Valentine’s Day, not only are long-stem roses available, but also other ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular Dystrophy Association and ... launched the 14th annual “Appetite for a Cure” campaign on Feb. 1 to ... and related diseases that severely limit strength and mobility. , Now through ...
(Date:2/5/2016)... Miami, Florida (PRWEB) , ... February 05, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is poised to once again host, Swirl, A Wine Tasting Event ...
(Date:2/5/2016)... ... ... Give To Cure today announced that it is working with ... Cure’s campaign that is crowdfunding clinical trials to help find cures faster for Alzheimer’s ... smart device. In 2015 alone, Venmo processed $7.5 billion in transactions among users. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):